Loading
Latest filing published 08 Sept 2023 for Arch Therapeutics, Inc., €2,610.
No signal scores available.
Not enough history yet: 0 closed purchases, at least 2 are needed.
Laurence Hicks appears in our data through filings on Arch Therapeutics, Inc. shares, published by SEC (Form 4). Over a trading history stretching from 6 July 2022 to 31 August 2023, the count stands at 2 filings.
On the market, this insider has only ever bought: 1 purchase, €2,610 in total. Unlike grants, an open-market purchase is paid for by the insider, at the market price. The rest of the record consists of 1 share grant. In 2023 alone, the filings show 1 purchase and no sales.
The latest filing, published on 8 September 2023, reports an open-market purchase of €2,610 in Arch Therapeutics, Inc. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
2 of 2 declarations